Activation of metabotropic glutamate receptor 5 improves recovery after spinal cord injury in rodents

Annals of Neurology

Volumn 66, Issue 1, 2009, Pages 63-74

  Byrnes, Kimberly R ^a,b   Stoica, Bogdan ^a   Riccio, Angela ^a   Pajoohesh Ganji, Ahdeah ^a   Loane, David J ^a   Faden, Alan I ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 HYDROXYPHENYLGLYCINE; CELL PROTEIN; ED1 PROTEIN; GALECTIN 3; IBA 1 PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONAL ASSESSMENT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROGLIA; MOTOR COORDINATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SPINAL CORD INJURY; STATISTICAL ANALYSIS; WEIGHT BEARING; WESTERN BLOTTING; WHITE MATTER;

ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD11B; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; ECTODYSPLASINS; EMBRYO, MAMMALIAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCITATORY AMINO ACID AGONISTS; GALECTIN 3; GENE EXPRESSION REGULATION; GLYCINE; LIPOPOLYSACCHARIDES; MAGNETIC RESONANCE IMAGING; MALE; MICROGLIA; NEURONS; NITRIC OXIDE; PHENYLACETATES; PHOSPHOPYRUVATE HYDRATASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECOVERY OF FUNCTION; SPINAL CORD INJURIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69249101175     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21673     Document Type: Article

References (58)

1. Dumont RJ, Okonkwo DO, Verma S, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001;24:254-264.
2. Tator CH. Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. J Spinal Cord Med 1996;19:206-214.
3. Popovich PG, Guan Z, McGaughy V, et al. The neuropathological and behavioral consequences of intraspinal microglial/ macrophage activation. J Neuropathol Exp Neurol 2002;61: 623-633.
4. Keane RW, Davis AR, Dietrich WD. Inflammatory and apoptotic signaling after spinal cord injury. J Neurotrauma 2006; 23:335-344.
5. Hausmann ON. Post-traumatic inflammation following spinal cord injury. Spinal Cord 2003;41:369-378.
6. Bethea JR, Castro M, Keane RW, et al. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci 1998;18:3251-3260.
7. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005;76:77-98.
8. Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun Rev 2004;3:251-260.
9. He Y, Imam SZ, Dong Z, et al. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem 2003;86: 1338-1345.
10. Iravani MM, Kashefi K, Mander P, et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002;110:49-58.
11. Jeohn GH, Kim WG, Hong JS. Time dependency of the action of nitric oxide in lipopolysaccharide-interferon-gamma-induced neuronal cell death in murine primary neuron-glia co-cultures. Brain Res 2000;880:173-177.
12. Munch G, Gasic-Milenkovic J, Dukic-Stefanovic S, et al. Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Exp Brain Res 2003;150:1-8.
13. Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005;1034:11-24.
14. Taylor DL, Jones F, Kubota ES, Pocock JM. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005;25:2952-2964.
15. Juurlink BH, Paterson PG. Review of oxidative stress in brain and spinal cord injury: suggestions for pharmacological and nutritional management strategies. J Spinal Cord Med 1998;21: 309-334.
16. Lewen A, Matz P, Chan PH. Free radical pathways in CNS injury. J Neurotrauma 2000;17:871-890.
17. Tian DS, Xie MJ, Yu ZY, et al. Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. Brain Res 2007; 1135:177-185.
18. Dijkstra S, Duis S, Pans IM, et al. Intraspinal administration of an antibody against CD81 enhances functional recovery and tissue sparing after experimental spinal cord injury. Exp Neurol 2006;202:57-66.
19. Walker K, Reeve A, Bowes M, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology 2001;40:10-19.
20. Gwak YS, Hulsebosch CE. Upregulation of Group I metabotropic glutamate receptors in neurons and astrocytes in the dorsal horn following spinal cord injury. Exp Neurol 2005;195: 236-243.
21. Biber K, Laurie DJ, Berthele A, et al. Expression and signaling of group I metabotropic glutamate receptors in astrocytes and microglia. J Neurochem 1999;72:1671-1680.
22. Taylor DL, Diemel LT, Cuzner ML, Pocock JM. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J Neurochem 2002;82:1179-1191.
23. Taylor DL, Diemel LT, Pocock JM. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity. J Neurosci 2003;23:2150-2160.
24. Movsesyan VA, Faden AI. Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury. J Neurotrauma 2006;23:117-127.
25. Allen JW, Ivanova SA, Fan L, et al. Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury. J Pharmacol Exp Ther 1999;290:112-120.
26. Faden AI, Ivanova SA, Yakovlev AG, Mukhin AG. Neuroprotective effects of group III mGluR in traumatic neuronal injury. J Neurotrauma 1997;14:885-895.
27. Vernon AC, Zbarsky V, Datla KP, et al. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo. J Pharmacol Exp Ther 2007;320:397-409.
28. Folbergrova J, Druga R, Otahal J, et al. Seizures induced in immature rats by homocysteic acid and the associated brain damage are prevented by group II metabotropic glutamate receptor agonist (2R,4R)-4-aminopyrrolidine-2,4- dicarboxylate. Exp Neurol 2005;192:420-436.
29. Bond A, Ragumoorthy N, Monn JA, et al. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neurosci Lett 1999;273:191-194.
30. Byrnes KR, Stoica B, Loane DJ, et al. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 2009;57:550-560.
31. Yakovlev AG, Faden AI. Sequential expression of c-fos protooncogene, TNF-alpha, and dynorphin genes in spinal cord following experimental traumatic injury. Mol Chem Neuropathol 1994;23:179-190.
32. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res 2001; 922:173-179.
33. Basso DM, Beattie MS, Bresnahan JC, et al. MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. J Neurotrauma 1996;13:343-359.
34. Faden AI, Halt P. Platelet-activating factor reduces spinal cord blood flow and causes behavioral deficits after intrathecal administration in rats through a specific receptor mechanism. J Pharmacol Exp Ther 1992;261:1064-1070.
35. Kerasidis H, Wrathall JR, Gale K. Behavioral assessment of functional deficit in rats with contusive spinal cord injury. J Neurosci Methods 1987;20:167-179.
36. Byrnes KR, Stoica BA, Fricke S, et al. Cell cycle activation contributes to post-mitotic cell death and secondary damage after spinal cord injury. Brain 2007;130:2977-2992.
37. Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997;377:443-464.
38. Byrnes KR, Garay J, Di Giovanni S, et al. Expression of two temporally distinct microglia-related gene clusters after spinal cord injury. Glia 2006;53:420-433.
39. Mukhin AG, Ivanova SA, Allen JW, Faden AI. Mechanical injury to neuronal/glial cultures in microplates: role of NMDA receptors and pH in secondary neuronal cell death. J Neurosci Res 1998;51:748-758.
40. Lalancette-Hebert M, Gowing G, Simard A, et al. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 2007;27:2596-2605.
41. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993;151:1473-1481.
42. Kim WG, Mohney RP, Wilson B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000;20:6309-6316.
43. Allen JW, Knoblach SM, Faden AI. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro. Cell Death Differ 2000;7:470-476.
44. Liu B, Du L, Kong LY, et al. Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience 2000;97:749-756.
45. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004;24:2182-2190.
46. Sribnick EA, Wingrave JM, Matzelle DD, et al. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res 2005;82: 283-293.
47. Genovese T, Esposito E, Mazzon E, et al. Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. Shock 2008;30:142-152.
48. Cronin M, Anderson PN, Cook JE, et al. Blocking connexin43 expression reduces inflammation and improves functional recovery after spinal cord injury. Mol Cell Neurosci 2008;39: 152-160.
49. Yune TY, Lee JY, Jung GY, et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007; 27:7751-7761.
50. Schwartz M, Yoles E. Immune-based therapy for spinal cord repair: autologous macrophages and beyond. J Neurotrauma 2006;23:360-370.
51. Yaguchi M, Ohta S, Toyama Y, et al. Functional recovery after spinal cord injury in mice through activation of microglia and dendritic cells after IL-12 administration. J Neurosci Res 2008; 86:1972-1980.
52. Horn KP, Busch SA, Hawthorne AL, et al. Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. J Neurosci 2008;28:9330-9341.
53. Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/ macrophage activation. PLoS Med 2008;5:e171.
54. Farooque M, Isaksson J, Olsson Y. Improved recovery after spinal cord injury in neuronal nitric oxide synthase-deficient mice but not in TNF-alpha-deficient mice. J Neurotrauma 2001;18: 105-114.
55. Kim GM, Xu J, Song SK, et al. Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci 2001;21: 6617-6625.
56. Byrnes KR, Loane DJ, Faden AI. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders. Neurotherapeutics 2009;6:94-107.
57. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25.
58. Yakovlev AG, Faden AI. Caspase-dependent apoptotic pathways in CNS injury. Mol Neurobiol 2001;24:131-144.